The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

The market continued its lacklustre run throughout the day, crossing the line in the red.

The ASX200 closed down 0.12 per cent or 8.4 points to 7,255.7.

In the green

Healthcare led the sectors today, with heavyweight CSL (CSL) gaining a little over a per cent to close at $303.20

Uranium miner, Paladin Energy (PDN) had a strong session, gaining more than eight per cent. It’s been lifting since it released its presentation to the Macquarie Australia Conference on May 4.

And engineering group, Monadelphous (MND) also had a positive day, up more than 3 and a half per cent to close at $13.30.

In the red

Seven of the 11 sectors were down today, with communication services falling furthest.

Bank of Queensland (BOQ) tumbled nearly four and a half per cent today on trading ex-dividend, which means those buying on market today won’t get the latest dividend.  

And artificial intelligence specialist, Appen (APX) fell more than 28 per cent after the company announced a drop in revenue with EBITDA for the first half of FY23 expected to be materially lower year on year.

An unaudited update suggested revenue for the four months to April would be more than 20 per cent lower at $95.7 million.

Appen cited challenging external operating and macroeconomic conditions for the drop.

More From The Market Online
The Market Online Video

Tuesday’s HotCopper Trends: Pancontinental price buckles, Advance hits gold | March 18, 2025

The ASX has been up 0.3% at 7,877 points.
The Market Online Video

Expert Exchange: Saul Eslake breaks down the risks of investing in the ASX

Like any investment, share market investing has a risk and reward-relationship.
A huge ship built by Austal cruises through the blue ocean.

Take two: Korea’s Hanwha hasn’t given up on grabbing Austal stake just yet

Heavyweight South Korean business conglomerate Hanwha Group is taking another swing at Austal Ltd (ASX:ASB) half a year after its last takeover play
3D image of ovarian cancer

CLEO Diagnostics kicks off IP transfer for ovarian cancer blood tests to US manufacturers

CLEO Diagnostics has commenced the 'technology transfer' process to a US-based manufacturing partner ahead of commercialisation.